Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 27, 2026
TickeronGET DAILY SIGNALS
Pulmonx (LUNG) Delivers +6% Revenue Growth and Narrows Losses in Q3 2026

Pulmonx (LUNG) Delivers +6% Revenue Growth and Narrows Losses in Q3 2026

Key Takeaways

  • Pulmonx reported third quarter 2026 revenue of $22.8 million, up 6% year over year and above the consensus estimate of $21.93 million.
  • Net loss narrowed 40% to $8.4 million, or $0.19 per share, beating the consensus expectation of a $0.26 per-share loss.
  • Gross margin improved to 76%, and management raised its full-year 2026 gross margin outlook to approximately 77%.
  • Operating expenses fell 18% to $24.9 million, underscoring the company's cost-reduction efforts.
  • Management reiterated full-year 2026 revenue guidance of $90 million to $92 million.
  • Adjusted EBITDA loss narrowed nearly 60% to $3.5 million.

Earnings Context and Why It Matters

Pulmonx Corporation (LUNG) is a medical technology company focused on minimally invasive treatments for chronic obstructive pulmonary disease (COPD), a progressive lung condition. Its flagship Zephyr Endobronchial Valve treats patients with severe emphysema. The third quarter of 2026 marked a pivotal moment: the company returned to year-over-year revenue growth in both its U.S. and international businesses for the first time since its current leadership team rejoined the company. Coming after a period of commercial reset, this report offers investors a key signal on whether Pulmonx's rebuilt sales organization and cost discipline can translate into sustained top-line expansion and a clearer path toward profitability. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Reported Results

Pulmonx reported total worldwide revenue of $22.8 million for the third quarter ended September 30, 2026, a 6% increase from $21.5 million in the prior-year period and above the $21.93 million consensus estimate. U.S. revenue rose 7% to $14.9 million, while international revenue increased 5% to $7.9 million. Excluding China, international markets grew approximately 9% year over year.

GAAP net loss narrowed to $8.4 million, or $0.19 per share, compared with a net loss of $14.0 million, or $0.34 per share, in the same quarter last year. The result beat the consensus EPS estimate of a $0.26 loss.

Gross margin was 76%, up from 75% a year earlier, while total operating expenses declined 18% to $24.9 million. Adjusted EBITDA loss narrowed to $3.5 million from $8.2 million, reflecting meaningful operating leverage. The company ended the quarter with $52.7 million in cash and cash equivalents.

Pulmonx also updated its outlook, reiterating full-year 2026 revenue guidance of $90 million to $92 million and raising its gross margin expectation to approximately 77%. Full-year operating expenses are now expected to land between $108 million and $109 million.

Market Reaction and Investor Sentiment

The market responded favorably to Pulmonx's third-quarter results. According to Investing.com, shares jumped roughly 13% after the report as investors rewarded the company's return to revenue growth, the EPS beat, and the narrowed losses. Sentiment has been supported by Pulmonx's consistent record of exceeding consensus EPS estimates and by management's confirmation of full-year guidance. The addition of eight new U.S. treating centers during the quarter and the renewed China registration certificate also reinforced confidence that commercial momentum is rebuilding. Investors appeared to interpret the results as evidence that the company's restructuring and cost-reduction strategy is gaining traction. From what I see, this kind of reaction often signals building conviction when fundamentals align with guidance.

Forward Outlook and Key Factors to Monitor

Looking ahead, several factors will shape Pulmonx's trajectory through the remainder of 2026 and into 2027. First, investors should monitor the productivity ramp of the rebuilt U.S. sales force. Management indicated that substantially all open U.S. sales positions have been filled, but average sales representative tenure remains relatively short, meaning continued execution will be central to sustaining growth.

Second, the China business represents a potential near-term catalyst. With the registration certificate renewed, Pulmonx expects to resume shipments to its distributor by early next year, which could add incremental revenue as the region comes back online.

Third, watch progress on the AeriSeal platform. Enrollment in the CONVERT2 pivotal trial continues, and management views AeriSeal as a market-expansion opportunity that could broaden the company's addressable market by roughly 20%.

Finally, keep an eye on margins and cash usage. Pulmonx now expects roughly $22 million of cash burn for full-year 2026, a 30% reduction from 2025, and raised its gross margin outlook to about 77%. Sustained operating leverage combined with renewed revenue growth will be the key test of whether the company can continue narrowing losses toward its long-term profitability goals. I’m watching this closely as execution here could define the stock’s next leg higher.

Using Tickeron’s AI Tools for Deeper Analysis

In my view, tools like Tickeron’s AI Screener can help investors quickly compare LUNG against peers on metrics such as revenue trends, margin expansion, and technical signals. I often run similar screens when evaluating medtech names to spot patterns that might not stand out in standard reports. This approach has added useful context to my review of the quarter without replacing the core fundamental work.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: LUNG

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


LUNG's Indicator enters downward trend

The Aroon Indicator for LUNG entered a downward trend on October 23, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 202 similar instances where the Aroon Indicator formed such a pattern. In 185 of the 202 cases the stock moved lower. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for LUNG moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 27 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 84%.

The Moving Average Convergence Divergence Histogram (MACD) for LUNG turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 44 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LUNG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

LUNG broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The Momentum Indicator moved above the 0 level on November 19, 2026. You may want to consider a long position or call options on LUNG as a result. In 70 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.

LUNG moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for LUNG crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.

Following a +7.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where LUNG advanced for three days, in 214 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.805) is normal, around the industry mean (4.142). P/E Ratio (-2.226) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.932) is also within normal values, averaging (40.124).

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. LUNG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LUNG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -11%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -18%. MXCT experienced the highest price growth at 15%, while CODX experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -35%. For the same stocks of the Industry, the average monthly volume growth was -2% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 64
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 16 (-100 ... +100)
Real Time Patterns 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry MedicalNursingServices

Industry
N/A
Address
700 Chesapeake Drive
Phone
+1 650 364-0400
Employees
296
Web
https://www.pulmonx.com
Interact to see
Advertisement
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.
Intel Corporation has delivered dramatically stronger relative price momentum over the past year, while SPY offers broad, diversified market exposure with far lower single-stock volatility. INTC's rally has been driven by a strategic turnaround under new leadership, backed by multi-billion-dollar investments from Nvidia, SoftBank, and the U.S. government.